Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Clinical Pathology"
DOI: 10.1093/ajcp/aqy028
Abstract: Objectives Pathologic complete response (pCR) rate after neoadjuvant chemotherapy was compared between 141 estrogen receptor (ER)-negative (43%), 41 low ER+ (13%), 47 moderate ER+ (14%), and 98 high ER+ (30%) tumors. Methods Human epidermal growth… read more here.
Keywords: pcr rate; response; receptor positive; rate ... See more keywords
Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz246.139
Abstract: Abstract Background Preop CTRT is the standard of treatment of LARC and it results in significant tumor downstaging and local control with a complete pathological response (pCR) rate of about 15%. Immunotherapy can lead up… read more here.
Keywords: pcr rate; preop; study; preop ctrt ... See more keywords
The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Management and Research"
DOI: 10.2147/cmar.s168573
Abstract: Background In a Phase II clinical trial, we reported the effectiveness and safety of a sandwich neoadjuvant treatment based on a modified oxaliplatin plus capecitabine (XELOX) regimen for locally advanced rectal cancer (LARC). The pathologic… read more here.
Keywords: pcr rate; trial; long term; treatment ... See more keywords
Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14184508
Abstract: Simple Summary Approximately 15–25% of breast cancers are human epidermal growth factor receptor 2 (HER2)-positive. With the progress in medicine, promising results have been shown by dual targeted therapy with new drugs in the neoadjuvant… read more here.
Keywords: pcr rate; therapy; breast cancer; tch ... See more keywords
Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer
Sign Up to like & getrecommendations! Published in 2023 at "Oncology Letters"
DOI: 10.3892/ol.2023.13741
Abstract: Neoadjuvant chemoradiotherapy (nCRT) has been shown to reduce tumor burden and achieve tumor regression in patients with esophageal cancer (ESC). However, the most beneficial time interval between the administration of nCRT and surgery remains unclear.… read more here.
Keywords: time; prolonged time; surgery; survival ... See more keywords